Centrient Pharmaceuticals International B.V.
Centrient Pharmaceuticals International B.V. is a private limited company (besloten vennootschap) registered in the Netherlands under Chamber of Commerce (KvK) number 35008465, with its registered office at Alexander Fleminglaan 1, 2613 AX Delft. The company was first registered under its current name in December 2017 and its registration status is listed as active.
Trading as Centrient Pharmaceuticals, the business traces its roots to Gist-Brocades, founded in 1869, and operated for a period as DSM Sinochem Pharmaceuticals, a joint venture between Royal DSM and Sinochem Group. It adopted the Centrient Pharmaceuticals name following a change of ownership completed in 2018.
Centrient Pharmaceuticals is a business-to-business supplier of foundational medicines, principally sustainable, fermentation-based antibiotics, next-generation statins and anti-fungal active pharmaceutical ingredients (APIs). It also supplies pharmaceutical intermediates and finished dosage forms such as tablets and capsules to generic-drug manufacturers and healthcare companies worldwide. The Centrient group reports operations across four continents and approximately 1,800 employees, with manufacturing and commercial sites in the Netherlands, Spain, India, China and Mexico; these figures describe the wider Centrient group rather than this legal entity alone.
The Centrient group’s registered office and a production site are located in Delft, Netherlands, while the group’s corporate leadership has been reported at an office address in Rotterdam; only the Delft address is confirmed for this specific legal entity by its Chamber of Commerce registration.
In January 2024, Bloomberg reported that Centrient’s private-equity owner was exploring a possible sale of the business valued at up to approximately EUR 1 billion; public sources reviewed for this profile do not confirm that a transaction has since completed.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Centrient Pharmaceuticals International B.V.
Centrient Pharmaceuticals International B.V. sits within a Dutch holding structure in which its immediate parent, according to corporate-linkage records reviewed for this profile, is Centrient Holding B.V. (Netherlands). That holding company in turn sits beneath a chain of Dutch entities using the "BCPE Max Dutch" naming convention (JVCo, TopCo, MidCo1 and MidCo2), a naming pattern consistent with Bain Capital Private Equity holding structures. Direct shareholding percentages within this chain are not disclosed in the sources reviewed.
Bain Capital Private Equity’s control of the wider Centrient group is independently confirmed: Bain Capital Private Equity announced its acquisition of the group (then DSM Sinochem Pharmaceuticals) on 29 June 2018, and Centrient’s own published Supervisory Board as of this review includes two named Bain Capital representatives. A Bloomberg report from January 2026 (referring to events reported in January 2024) described Centrient as still being owned by Bain Capital at that time.
No other named institutional co-investor could be independently verified from primary or reputable secondary sources for this specific legal entity as part of this review; any additional consortium participants should therefore be treated as unconfirmed rather than assumed.
Ultimate beneficial ownership
No individual ultimate beneficial owner could be reliably identified from the sources reviewed. Dutch UBO Register filings are not publicly searchable in full, and no natural person was named as a beneficial owner in the company or press sources reviewed.
Data availability
Shareholder disclosure for this entity is Partial: the immediate corporate parent and a private-equity sponsor (Bain Capital Private Equity) are reasonably well evidenced, but share percentages and any additional consortium investors are not publicly confirmed. The Netherlands restricts public access to full UBO Register filings, which limits independent verification of beneficial ownership.
Sources
- Centrient Pharmaceuticals, "Bain Capital Private Equity acquires DSM Sinochem Pharmaceuticals" (centrient.com/media), published 29 June 2018, retrieved 17 September 2026
- Centrient Pharmaceuticals, "Leadership" (centrient.com/about-us/leadership), retrieved 17 September 2026
- Bloomberg, "Bain Is Said to Explore EUR 1 Billion Sale of Centrient Pharma", published 3 January 2024, retrieved 17 September 2026
Officers
1
One officer is currently on record for Centrient Pharmaceuticals International B.V., filed with Netherlands Chamber of Commerce (KvK). K.M.F. Rotthier serves as Bestuurder (director).
The source filing doesn't specify representation authority — whether officers can act individually or must sign jointly to bind the company — so that detail isn't available here.
Group Structure
Group structure of Centrient Pharmaceuticals International B.V.
Centrient Pharmaceuticals International B.V. is not an independent company; it operates as part of the wider Centrient Pharmaceuticals group under private-equity ownership. Corporate-linkage data reviewed for this profile shows Centrient Holding B.V. (Netherlands, registration number 71889027) as the immediate parent, sitting beneath a further chain of Dutch entities (BCPE Max Dutch MidCo2 B.V., MidCo1 B.V., TopCo B.V. and JVCo B.V.), a naming pattern consistent with the Bain Capital Private Equity ownership confirmed separately for this group. Ownership percentages within this chain are not disclosed in the sources reviewed.
Below Centrient Pharmaceuticals International B.V., corporate-linkage records list a number of operating entities, several of which correspond to manufacturing or commercial locations that Centrient’s own website confirms as part of its global footprint, including sites in China (Changchun and Zibo) and Spain, and a commercial entity in Mexico. This overlap between the linkage data and Centrient’s published site network supports treating these as verified group entities, though exact ownership and voting percentages are not publicly disclosed.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Centrient Holding B.V. | NL | 71889027 | Immediate parent | Not disclosed | Active | 2026-09-17 |
| Centrient Pharmaceuticals Netherlands B.V. | NL | 14090826 | Direct subsidiary | Not disclosed | Active | 2026-09-17 |
| Centrient Pharmaceuticals (Zibo) Co., Ltd. | CN | 370300400001818 | Indirect subsidiary (manufacturing site) | Not disclosed | Active | 2026-09-17 |
| Centrient Pharmaceuticals Spain S.A. | ES | A60607363 | Indirect subsidiary | Not disclosed | Active | 2026-09-17 |
| Fersinsa GB, S.A. de C.V. | MX | FGB910808FU9 | Indirect subsidiary | Not disclosed | Active | 2026-09-17 |
Recent structural changes
- 29 June 2018: Bain Capital Private Equity announced its agreement to acquire the group (then DSM Sinochem Pharmaceuticals) from Koninklijke DSM and Sinochem Group; the acquisition subsequently completed and the group was renamed Centrient Pharmaceuticals. Source: Centrient Pharmaceuticals media release, June 2018.
- January 2024 (reported January 2026 in retrospect coverage): Bloomberg reported that Bain Capital was exploring a possible sale of Centrient valued at up to approximately EUR 1 billion; no completed transaction is confirmed by the sources reviewed. Source: Bloomberg, January 2024.
Data availability
Group-structure information for this entity is Partial: the immediate Dutch parent chain and several operating subsidiaries are corroborated across corporate-linkage data and Centrient’s own published site network, but ownership and voting percentages are not publicly disclosed, and the full extent of the group beyond the entities listed here could not be independently confirmed.
Sources
- Centrient Pharmaceuticals, "Our global footprint" (centrient.com/about-us/global-network/our-global-footprint), retrieved 17 September 2026
- Centrient Pharmaceuticals, "Bain Capital Private Equity acquires DSM Sinochem Pharmaceuticals" (centrient.com/media), published 29 June 2018, retrieved 17 September 2026
- Bloomberg, "Bain Is Said to Explore EUR 1 Billion Sale of Centrient Pharma", published 3 January 2024, retrieved 17 September 2026
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
BCPE Max Dutch JVCo B.V.
Netherlands
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does Centrient Pharmaceuticals International B.V. do?
Centrient Pharmaceuticals International B.V. (KvK 35008465, Delft, Netherlands) is part of the Centrient Pharmaceuticals group, a B2B supplier of antibiotics, next-generation statins and anti-fungal active pharmaceutical ingredients (APIs), intermediates and finished dosage forms, formerly known as DSM Sinochem Pharmaceuticals.
Who owns Centrient Pharmaceuticals International B.V.?
Immediate parent is Centrient Holding B.V. (Netherlands). The group has been controlled by Bain Capital Private Equity since a June 2018 acquisition; exact shareholding percentages are not publicly disclosed.
Who is Centrient Pharmaceuticals International B.V.'s UBO (Ultimate Beneficial Owner)?
No individual ultimate beneficial owner could be reliably identified from the sources reviewed. Dutch UBO Register filings are not publicly searchable in full, and no natural person was named as a beneficial owner in the company or press sources reviewed.
What is Centrient Pharmaceuticals International B.V.'s company registration number?
Centrient Pharmaceuticals International B.V.'s registration number is 35008465, filed with Netherlands Chamber of Commerce (KvK) in Netherlands. Its current status on the register is active.
Is Centrient Pharmaceuticals International B.V. still an active company?
Centrient Pharmaceuticals International B.V.'s status on Netherlands Chamber of Commerce (KvK) is listed as active.
What is Centrient Pharmaceuticals International B.V.'s registered address?
The registered address on file for Centrient Pharmaceuticals International B.V. is Delft, Netherlands.
What legal structure is Centrient Pharmaceuticals International B.V. registered as?
Centrient Pharmaceuticals International B.V. is registered as a Private limited company (Ltd.) in Netherlands.
Is Centrient Pharmaceuticals International B.V. listed on a stock exchange?
Privately held. Not listed on any stock exchange; owned through a private-equity holding structure.
Who are the officers/directors of Centrient Pharmaceuticals International B.V.?
One officer is currently on record for Centrient Pharmaceuticals International B.V., filed with Netherlands Chamber of Commerce (KvK). K.M.F. Rotthier serves as Bestuurder (director).
Does Centrient Pharmaceuticals International B.V. have a parent company or subsidiaries?
Part of a Dutch holding chain beneath Centrient Holding B.V. and Bain Capital Private Equity-linked entities (BCPE Max Dutch MidCo1/MidCo2/TopCo/JVCo). Verified group operating entities include sites in the Netherlands, China (Zibo, Changchun), Spain and Mexico.
Can Zavia monitor changes to Centrient Pharmaceuticals International B.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Netherlands Chamber of Commerce (KvK). Zavia's monitoring API can track changes to Centrient Pharmaceuticals International B.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Centrient Pharmaceuticals International B.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Netherlands, so records like Centrient Pharmaceuticals International B.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Netherlands Chamber of Commerce (KvK) and was last synced on 17 September 2026.